Copperwynd Financial LLC Buys 576 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Copperwynd Financial LLC lifted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 11.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 5,556 shares of the pharmaceutical company's stock after acquiring an additional 576 shares during the period. Copperwynd Financial LLC's holdings in Vertex Pharmaceuticals were worth $2,237,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the company. Prime Capital Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 2.3% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 3,456 shares of the pharmaceutical company's stock worth $1,607,000 after purchasing an additional 78 shares in the last quarter. Kovack Advisors Inc. raised its stake in shares of Vertex Pharmaceuticals by 3.7% during the 3rd quarter. Kovack Advisors Inc. now owns 1,257 shares of the pharmaceutical company's stock worth $585,000 after purchasing an additional 45 shares in the last quarter. KBC Group NV raised its stake in shares of Vertex Pharmaceuticals by 11.1% during the 3rd quarter. KBC Group NV now owns 96,727 shares of the pharmaceutical company's stock worth $44,986,000 after purchasing an additional 9,685 shares in the last quarter. Curi RMB Capital LLC raised its stake in shares of Vertex Pharmaceuticals by 4.7% during the 3rd quarter. Curi RMB Capital LLC now owns 1,580 shares of the pharmaceutical company's stock worth $735,000 after purchasing an additional 71 shares in the last quarter. Finally, OneDigital Investment Advisors LLC raised its stake in shares of Vertex Pharmaceuticals by 62.7% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 2,817 shares of the pharmaceutical company's stock worth $1,310,000 after purchasing an additional 1,086 shares in the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Transactions at Vertex Pharmaceuticals

In other news, EVP Ourania Tatsis sold 244 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $455.06, for a total value of $111,034.64. Following the transaction, the executive vice president now directly owns 67,695 shares of the company's stock, valued at $30,805,286.70. The trade was a 0.36 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP David Altshuler sold 3,231 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the transaction, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 4,315 shares of company stock valued at $2,121,012 in the last three months. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Price Performance

Shares of Vertex Pharmaceuticals stock traded up $0.29 during midday trading on Wednesday, hitting $512.52. 1,123,986 shares of the company were exchanged, compared to its average volume of 1,212,340. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market cap of $131.61 billion, a P/E ratio of -232.96, a PEG ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 52 week low of $377.85 and a 52 week high of $519.88. The firm has a 50 day simple moving average of $462.05 and a 200-day simple moving average of $461.95.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its earnings results on Monday, February 10th. The pharmaceutical company reported $3.54 EPS for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. Research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on VRTX shares. Bank of America cut their price target on Vertex Pharmaceuticals from $545.00 to $522.00 and set a "buy" rating for the company in a research note on Thursday, December 19th. William Blair reaffirmed an "outperform" rating on shares of Vertex Pharmaceuticals in a research report on Friday, January 31st. Stifel Nicolaus boosted their price target on Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a "hold" rating in a research report on Monday, December 16th. Scotiabank boosted their price target on Vertex Pharmaceuticals from $433.00 to $450.00 and gave the stock a "sector perform" rating in a research report on Tuesday, February 11th. Finally, StockNews.com raised Vertex Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Tuesday, March 11th. Ten investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $506.70.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.